Celadon Pharmaceuticals Regulatory News (CEL)

29 Sep 2005 07:00

Celsis International PLC29 September 2005 CELSIS INTERNATIONAL PLC Pre-close Trading Update 29 September 2005: Celsis International plc, the rapid microbial detection andanalytical services company, today announces an update on trading prior to thecommencement of its close period. Celsis has made good progress in the first half of the year and as a result thecompany is on track to perform in line with the Board's expectations for the sixmonths to 30 September 2005. The Product Group division continues to achieve good growth with the LaboratoryGroup maintaining its last year second half performance following a slightimpact from a slow down in pharmaceutical companies spending. Overall thecompany has seen robust trading during this financial period, especiallycompared to the extremely strong first half year results in 2004. Jay LeCoque, Chief Executive Officer, Celsis International plc commented: "I am pleased to report that Celsis has performed well during the first half ofthis financial year and I look forward to a successful second half. Our recent agreement with BioVentures to develop microarray and other rapidmicrobial detection systems demonstrates Celsis' commitment to remaining theworld leader in our field. These new technologies will enable Celsis tosignificantly expand its business both in existing as well as future newmarkets. Celsis' strong cash position means the company is well placed for future growthand I remain confident about the company's prospects." Celsis will announce its interim results for the six months to 30 September2005, on Tuesday 8 November 2005. There will be a presentation to analysts onthe day at 9.30am, held at Financial Dynamics, Holborn Gate, 26 SouthamptonBuildings, London, WC2A 1PB. Enquiries: Celsis International plc Tel: 01638 600 151Jay LeCoque, Chief Executive OfficerJenny Parsons, Corporate Communications Financial Dynamics Tel: 020 7831 3113Ben Atwell Notes to editors Celsis International plc Celsis International plc is a rapid microbial detection and analytical servicescompany operating through two divisions, the Product Group and the LaboratoryGroup. Using its proprietary enzyme technology, the Product Group is the world leaderin the provision of diagnostic systems for the rapid detection of microbialcontamination. It works in close collaboration with many of the world's leadingpharmaceutical, personal care and beverage companies, ensuring the safety andquality of products bound for consumers. The Laboratory Group providesoutsourced analytical testing services to pharmaceutical and biopharmaceuticalcompanies to ensure the stability and chemical composition of their products. In addition to ensuring product quality and safety for consumers, both divisionshave the capacity to deliver substantial cost savings to Celsis' customers. Byreducing the time it takes to test and release raw materials and finished goodsto the market place, Celsis' products facilitate increased manufacturingproductivity and improved supply chain management. Celsis International plc is listed on the London Stock Exchange (CEL.L).Further information can be found on the Company's website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange